SI3412672T1 - Kristalna oblika A 2-butoksi-7-(4-(pirolidin-1-ilmetil)benzil)-5H-pirolo(3,2-d)pirimidin -4-amina kot TLR7 agonist, postopek priprave in njena uporaba - Google Patents

Kristalna oblika A 2-butoksi-7-(4-(pirolidin-1-ilmetil)benzil)-5H-pirolo(3,2-d)pirimidin -4-amina kot TLR7 agonist, postopek priprave in njena uporaba

Info

Publication number
SI3412672T1
SI3412672T1 SI201730461T SI201730461T SI3412672T1 SI 3412672 T1 SI3412672 T1 SI 3412672T1 SI 201730461 T SI201730461 T SI 201730461T SI 201730461 T SI201730461 T SI 201730461T SI 3412672 T1 SI3412672 T1 SI 3412672T1
Authority
SI
Slovenia
Prior art keywords
pyrrolo
pyrrolidin
pyrimidin
ylmethyl
butoxy
Prior art date
Application number
SI201730461T
Other languages
English (en)
Inventor
Zhaozhong Ding
Fei Sun
Yinghu Hu
Yilong Zhou
Zheng Wang
Rui Zhao
Ling Yang
Original Assignee
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.,
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chia Tai Tianqing Pharmaceutical Group Co., Ltd., filed Critical Chia Tai Tianqing Pharmaceutical Group Co., Ltd.,
Publication of SI3412672T1 publication Critical patent/SI3412672T1/sl

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07BGENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
SI201730461T 2016-02-05 2017-02-04 Kristalna oblika A 2-butoksi-7-(4-(pirolidin-1-ilmetil)benzil)-5H-pirolo(3,2-d)pirimidin -4-amina kot TLR7 agonist, postopek priprave in njena uporaba SI3412672T1 (sl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN201610082029.8A CN107043379A (zh) 2016-02-05 2016-02-05 一种tlr7激动剂的晶型a、其制备方法和医药用途
EP17747004.4A EP3412672B1 (en) 2016-02-05 2017-02-04 Crystal form a of 2-butoxy-7-(4-(pyrrolidin-1-ylmethyl) benzyl)-5h-pyrrolo[3,2-d]pyrimidin-4-amine as tlr7 agonist, preparation method and use thereof
PCT/CN2017/072891 WO2017133684A1 (zh) 2016-02-05 2017-02-04 一种tlr7激动剂的晶型a、其制备方法和用途

Publications (1)

Publication Number Publication Date
SI3412672T1 true SI3412672T1 (sl) 2021-02-26

Family

ID=59499348

Family Applications (1)

Application Number Title Priority Date Filing Date
SI201730461T SI3412672T1 (sl) 2016-02-05 2017-02-04 Kristalna oblika A 2-butoksi-7-(4-(pirolidin-1-ilmetil)benzil)-5H-pirolo(3,2-d)pirimidin -4-amina kot TLR7 agonist, postopek priprave in njena uporaba

Country Status (28)

Country Link
US (2) US10442811B2 (sl)
EP (1) EP3412672B1 (sl)
JP (1) JP6889171B2 (sl)
KR (1) KR102393280B1 (sl)
CN (2) CN107043379A (sl)
AR (1) AR107548A1 (sl)
AU (1) AU2017215801B2 (sl)
BR (1) BR112018015880A2 (sl)
CA (1) CA3013518C (sl)
CL (1) CL2018002092A1 (sl)
DK (1) DK3412672T3 (sl)
EA (1) EA035951B1 (sl)
ES (1) ES2830443T3 (sl)
HK (1) HK1259170A1 (sl)
HR (1) HRP20201644T1 (sl)
HU (1) HUE051399T2 (sl)
IL (1) IL260968B (sl)
LT (1) LT3412672T (sl)
MX (1) MX2018009501A (sl)
NZ (1) NZ744884A (sl)
PH (1) PH12018501643A1 (sl)
PL (1) PL3412672T3 (sl)
PT (1) PT3412672T (sl)
SG (1) SG11201806683UA (sl)
SI (1) SI3412672T1 (sl)
TW (1) TWI754629B (sl)
UA (1) UA121161C2 (sl)
WO (1) WO2017133684A1 (sl)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MA44334A (fr) 2015-10-29 2018-09-05 Novartis Ag Conjugués d'anticorps comprenant un agoniste du récepteur de type toll
CN107043378A (zh) * 2016-02-05 2017-08-15 正大天晴药业集团股份有限公司 一种吡咯并[3,2-d]嘧啶类化合物的制备方法及其中间体
CN107043380A (zh) 2016-02-05 2017-08-15 正大天晴药业集团股份有限公司 一种tlr7激动剂的马来酸盐、其晶型c、晶型d、晶型e、制备方法和用途
CN107043379A (zh) * 2016-02-05 2017-08-15 正大天晴药业集团股份有限公司 一种tlr7激动剂的晶型a、其制备方法和医药用途
CN112105620A (zh) * 2018-05-25 2020-12-18 正大天晴药业集团股份有限公司 用于治疗肺癌的tlr7激动剂及其药物组合
BR112021015577A2 (pt) 2019-02-08 2021-10-05 Research & Business Foundation Sungkyunkwan University Complexo-colesterol agonista do receptor toll-like 7 ou 8 e uso do mesmo
EP3937944A1 (en) * 2019-03-15 2022-01-19 Chia Tai Tianqing Pharmaceutical Group Co.,Ltd Toll-like receptor agonists for use in the treatment of hepatitis b
EP3949967A4 (en) * 2019-04-23 2023-01-18 Chia Tai Tianqing Pharmaceutical Group Co., Ltd. SOLID PHARMACEUTICAL COMPOSITION WITH TLR7 AGONISTS
WO2021177679A1 (ko) 2020-03-02 2021-09-10 성균관대학교산학협력단 병원균 외벽 성분 기반 생병원체 모방 나노 입자 및 그 제조 방법
JP2023536954A (ja) 2020-08-04 2023-08-30 プロジェニア インコーポレイテッド 活性化部位が一時的に不活性化したトール様受容体7または8作用薬と機能性薬物の結合体およびその用途
EP4194008A1 (en) 2020-08-04 2023-06-14 Progeneer Inc. Kinetically acting adjuvant ensemble
CN116322751A (zh) 2020-08-04 2023-06-23 蛋白科技先锋 包含能够动力学控制的佐剂的mRNA疫苗

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3376479B2 (ja) * 1991-08-12 2003-02-10 武田薬品工業株式会社 縮合ピリミジン誘導体、その製造法および用途
WO2007024707A2 (en) * 2005-08-22 2007-03-01 The Regents Of The University Of California Tlr agonists
SG172060A1 (en) 2008-12-09 2011-07-28 Gilead Sciences Inc Modulators of toll-like receptors
CA2826295C (en) * 2011-02-04 2020-10-20 Duquesne University Of The Holy Spirit Bicyclic and tricyclic pyrimidine tyrosine kinase inhibitors with antitubulin activity and methods of treating a patient
WO2013103967A1 (en) * 2012-01-05 2013-07-11 Northeastern University Allosteric modulators of cb1 cannabinoid receptors
MX365114B (es) 2012-10-10 2019-05-23 Janssen Sciences Ireland Uc Derivados pirrolo[3,2-d]pirimidinicos para el tratamiento de infecciones viricas y otras enfermedades.
US9428512B2 (en) 2012-11-20 2016-08-30 Glaxosmithkline Llc Compounds
ES2632448T3 (es) * 2012-11-20 2017-09-13 Glaxosmithkline Llc Nuevos compuestos
HUE13857477T2 (hu) * 2012-11-20 2018-05-28 Glaxosmithkline Llc Új vegyületek
PT3137470T (pt) 2014-05-01 2021-06-24 Novartis Ag Compostos e composições como agonistas do recetor tipo toll 7
PL3190113T3 (pl) 2014-08-15 2021-10-25 Chia Tai Tianqing Pharmaceutical Group Co., Ltd. Związki pirolopirymidynowe stosowane jako agonista TLR7
CN105367576A (zh) 2014-08-15 2016-03-02 正大天晴药业集团股份有限公司 作为tlr7激动剂的吡咯并嘧啶化合物
CN107043380A (zh) 2016-02-05 2017-08-15 正大天晴药业集团股份有限公司 一种tlr7激动剂的马来酸盐、其晶型c、晶型d、晶型e、制备方法和用途
CN107043379A (zh) * 2016-02-05 2017-08-15 正大天晴药业集团股份有限公司 一种tlr7激动剂的晶型a、其制备方法和医药用途

Also Published As

Publication number Publication date
CA3013518A1 (en) 2017-08-10
DK3412672T3 (da) 2020-10-19
TWI754629B (zh) 2022-02-11
LT3412672T (lt) 2020-11-10
US20190040071A1 (en) 2019-02-07
HK1259170A1 (zh) 2019-11-29
JP6889171B2 (ja) 2021-06-18
MX2018009501A (es) 2018-12-11
EP3412672A4 (en) 2019-07-17
AR107548A1 (es) 2018-05-09
PH12018501643A1 (en) 2019-06-03
AU2017215801B2 (en) 2020-09-10
PL3412672T3 (pl) 2021-01-25
HUE051399T2 (hu) 2021-03-01
US20200039988A1 (en) 2020-02-06
CL2018002092A1 (es) 2018-12-07
EP3412672A1 (en) 2018-12-12
US10442811B2 (en) 2019-10-15
TW201728589A (zh) 2017-08-16
SG11201806683UA (en) 2018-09-27
BR112018015880A2 (pt) 2018-12-26
WO2017133684A1 (zh) 2017-08-10
HRP20201644T1 (hr) 2020-12-25
KR20180104117A (ko) 2018-09-19
CA3013518C (en) 2022-07-19
EP3412672B1 (en) 2020-07-15
EA201891768A1 (ru) 2019-01-31
ES2830443T3 (es) 2021-06-03
PT3412672T (pt) 2020-11-11
US10947245B2 (en) 2021-03-16
UA121161C2 (uk) 2020-04-10
IL260968B (en) 2022-05-01
CN108602831B (zh) 2020-11-03
EA035951B1 (ru) 2020-09-04
CN108602831B9 (zh) 2020-12-04
CN108602831A (zh) 2018-09-28
NZ744884A (en) 2022-09-30
KR102393280B1 (ko) 2022-05-02
AU2017215801A1 (en) 2018-08-23
JP2019505533A (ja) 2019-02-28
CN107043379A (zh) 2017-08-15

Similar Documents

Publication Publication Date Title
SI3412672T1 (sl) Kristalna oblika A 2-butoksi-7-(4-(pirolidin-1-ilmetil)benzil)-5H-pirolo(3,2-d)pirimidin -4-amina kot TLR7 agonist, postopek priprave in njena uporaba
SI3429591T1 (sl) Substituirani tieno(2,3-d)pirimidinski derivati kot inhibitorji menin-MLL in postopki uporabe
IL247949A0 (en) New histories of pyrazolopyrimidines and their use as malt1 inhibitors
EP3310339A4 (en) OPHTHALMIC FORMULATIONS OF TYROSINE KINASE INHIBITORS, METHOD OF USE THEREOF AND METHOD OF PRODUCTION THEREOF
IL253360A0 (en) New crystalline forms of neratinib malate and a process for their preparation
EP3096763A4 (en) Novel process for the preparation of dolutegravir and pharmaceutically acceptable salts thereof
EP3115361A4 (en) Heterocyclic compounds, and preparation method and use thereof
PH12018501641A1 (en) Tlr7 agonist trifluoroacetate salt and crystalline form b thereof, preparation methods and uses
PL3564208T3 (pl) Sposób wytwarzania pochodnych kwasu 2-(cykloheksenyleno)malonowego i ich zastosowanie
EP3265455A4 (en) CHEMICAL PROCESS FOR THE PREPARATION OF PYRIMIDINE DERIVATIVES AND INTERMEDIATE PRODUCTS THEREOF
IL268880A (en) Foliar feeding formulations and methods of using them
EP3151933A4 (en) Golf ball holder and method thereof
GB2555748B (en) Novel form of isoxadifen-ethyl, process for preparation and use thereof
EP3216791A4 (en) Polymorphic substance of yonkenafil hydrochloride, preparation method therefor, and composition and use thereof
GB2559718B (en) Novel crystalline form of tribenuron-methyl, process for preparation and use thereof
EP3199639A4 (en) Novel measurement method using kinase, and composition
EP3212611A4 (en) Crystal forms of verapamil hydrochloride
EP3097099A4 (en) An improved process for the preparation of trazodone and hydrochloride salt thereof
EP3175851A4 (en) Use of butenylphthalide, usage method thereof and method for preparing same into pharmaceutical composition
GB2565419B (en) Process for preparing novel crystalline form of mesosulfuron-methyl and use thereof
EP3461823A4 (en) PLX3397 HYDROCHLORIDE CRYSTAL FORM, MANUFACTURING METHOD AND USE THEREOF
GB201721201D0 (en) Process for preparing novel crystalline form of iodosulfuron-methyl-sodium and use
GB201720181D0 (en) Process for preparing novel crystalline form of metsulfuron-methyl and use thereof
AU2014904044A0 (en) Fitness article and method of use